Loading...
XKRX
068270
Market cap23bUSD
Apr 17, Last price  
159,300.00KRW
1D
0.13%
1Q
-11.50%
Jan 2017
48.32%
IPO
314.14%
Name

Celltrion Inc

Chart & Performance

D1W1MN
P/E
79.43
P/S
9.44
EPS
2,005.50
Div Yield, %
—
Shrs. gr., 5y
8.38%
Rev. gr., 5y
25.81%
Revenues
3.56t
+63.45%
60,083,990,00083,689,668,000145,551,443,000180,948,490,000279,041,703,540350,196,210,210226,207,868,890471,045,510,650603,412,768,880670,580,961,670949,079,965,210982,074,959,8001,128,459,877,8901,849,115,532,1101,911,601,263,0302,283,967,480,3902,176,431,531,3803,557,303,554,370
Net income
422.69b
-21.09%
2,287,845,00014,571,059,00058,544,421,000108,372,315,000167,808,722,000174,431,166,000102,454,821,000112,676,335,300154,089,612,460177,994,501,810368,221,994,000245,755,018,000301,030,347,000517,759,533,000579,464,583,810537,835,568,480535,647,963,950422,691,724,150
CFO
901.87b
+67.90%
2,608,539,00046,786,456,00044,953,989,00033,595,631,00062,759,965,00020,970,652,130137,081,056,410145,158,529,42077,566,858,430250,888,340,240485,980,718,000364,786,083,000473,993,887,710350,746,671,970911,159,432,330863,531,980537,158,606,189901,870,301,320
Dividend
Dec 27, 2023500 KRW/sh
Earnings
May 07, 2025

Profile

Celltrion, Inc., together with its subsidiaries, develops and produces therapeutics based on proteins including oncology treatment drugs in South Korea. The company markets Remsima, Truxima, and Herzuma products; generic pharmaceuticals; covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 for the treatment of asthma and urticaria that is in phase 1 clinical trial; CT-P17 for the treatment of rheumatoid arthritis, psoriatic arthritis, and IBD, which is in phase 3 clinical trial; CT-P16 for the treatment of metastatic colorectal cancer and breast cancer that is in phase 3 clinical trial; CT-P41 for the treatment of osteoporosis and bone loss, which is in phase 1 clinical trial; CT-P43 for the treatment of psoriasis, crohn's disease, and ulcerative colitis that is in phase 3 clinical trial; CT-P42 for the treatment of diabetic macular edema, which is in phase 3 clinical trial; CT-P27 for the treatment of pandemic/seasonal influenza that is in phase 2 clinical trial; CT-P59 for the treatment of COVID-19, which is in phase 3 clinical trial; and CT-G20 for the treatment of Cardiomyopathy that is in phase 1 clinical trial. Celltrion, Inc. has a partnership with Inhalon Biopharma, Inc. to develop IN-006, an inhaled form of regdanvimab for treating patients with COVID-19. The company was founded in 2002 and is headquartered in Incheon, South Korea.
URL
https://www.celltrion.com/
IPO date
Jul 19, 2005
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
3,557,303,554
63.45%
2,176,431,531
-4.71%
2,283,967,480
19.48%
Cost of revenue
2,532,193,274
1,437,508,864
1,511,126,636
Unusual Expense (Income)
NOPBT
1,025,110,281
738,922,667
772,840,845
NOPBT Margin
28.82%
33.95%
33.84%
Operating Taxes
157,233,501
131,389,280
94,826,673
Tax Rate
15.34%
17.78%
12.27%
NOPAT
867,876,780
607,533,387
678,014,172
Net income
422,691,724
-21.09%
535,647,964
-0.41%
537,835,568
-7.18%
Dividends
(103,604,042)
(51,663,582)
(102,450,966)
Dividend yield
0.25%
0.18%
0.46%
Proceeds from repurchase of equity
(417,686,933)
(911,488,389)
(270,687,025)
BB yield
1.03%
3.17%
1.22%
Debt
Debt current
2,086,991,663
1,783,304,274
637,864,075
Long-term debt
136,447,076
123,269,151
160,084,002
Deferred revenue
73,773,004
88,625,992
160,201,589
Other long-term liabilities
9,320,822
5,871,728
7,575,837
Net debt
1,066,218,854
922,215,263
128,952,175
Cash flow
Cash from operating activities
901,870,301
537,158,606
863,532
CAPEX
(135,058,629)
(210,046,190)
(311,985,700)
Cash from investing activities
(169,388,988)
(138,864,903)
(297,051,208)
Cash from financing activities
(353,044,311)
(385,114,627)
(350,219,428)
FCF
884,594,121
(1,541,609,128)
155,981,652
Balance
Cash
1,143,045,619
757,497,069
594,463,770
Long term investments
14,174,266
226,861,094
74,532,132
Excess cash
979,354,708
875,536,586
554,797,528
Stockholders' equity
4,105,709,222
4,539,898,044
6,964,992,837
Invested Capital
18,735,556,335
18,235,175,645
4,568,412,611
ROIC
4.69%
5.33%
16.54%
ROCE
5.14%
3.84%
15.08%
EV
Common stock shares outstanding
217,084
142,725
138,319
Price
187,500.00
-6.95%
201,500.00
25.55%
160,500.00
-18.94%
Market cap
40,703,187,562
41.53%
28,759,080,246
29.54%
22,200,176,548
-22.96%
EV
41,910,327,206
29,826,406,409
22,463,972,993
EBITDA
1,443,360,165
984,749,999
999,230,868
EV/EBITDA
29.04
30.29
22.48
Interest
75,572,283
9,665,286
7,507,535
Interest/NOPBT
7.37%
1.31%
0.97%